AAS
ESPR

Avantax Advisory Services’s Esperion Therapeutics ESPR Stock Holding History

Avantax Advisory Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$12.7K Buy
+12,877
New +$12.9K ﹤0.01% 2352

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Avantax Advisory Services's ESPR Position: Q2 2025 in Review

Avantax Advisory Services opened a new position in Esperion Therapeutics (ESPR) in Q2 2025: 12,877 shares worth $12.7K. The stake represents ﹤0.01% of the portfolio and ranks #2352 among its holdings.

163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Avantax Advisory Services held 12,877 shares of Esperion Therapeutics worth $12.7K as of Q2 2025.
  • Esperion Therapeutics was a new Avantax Advisory Services position in Q2 2025.
  • Esperion Therapeutics made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2352 holding.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.